187 related articles for article (PubMed ID: 10344623)
1. Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans.
Vree TB; van der Ven AJ
J Pharm Pharmacol; 1999 Mar; 51(3):239-48. PubMed ID: 10344623
[TBL] [Abstract][Full Text] [Related]
2. Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man.
Vree TB; Van Den Biggelaar-Martea M; Verwey-Van Wissen CP
J Pharm Pharmacol; 1995 Nov; 47(11):964-9. PubMed ID: 8708993
[TBL] [Abstract][Full Text] [Related]
3. Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid.
Vree TB; van den Biggelaar-Martea M; Verwey-van Wissen CP
J Chromatogr B Biomed Appl; 1994 Apr; 655(1):53-62. PubMed ID: 8061834
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of action of xipamide and its classification as a "low ceiling diuretic". Pharmacodynamic-pharmacokinetic studies in healthy volunteers and in kidney and liver patients].
Knauf H; Mutschler E
Arzneimittelforschung; 2005; 55(1):1-14. PubMed ID: 15727159
[TBL] [Abstract][Full Text] [Related]
5. Urine volume as a predicting factor for furosemide clearance during continuous infusion in AKI septic shock patients on hemodiafiltration.
Mariano F; Leporati M; Carignano P; Stella M; Vincenti M; Biancone L
J Nephrol; 2018 Dec; 31(6):889-897. PubMed ID: 30225802
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and pharmacodynamics of torasemide.
Knauf H; Mutschler E
Clin Pharmacokinet; 1998 Jan; 34(1):1-24. PubMed ID: 9474471
[TBL] [Abstract][Full Text] [Related]
7. High-performance liquid chromatographic determination and identification of acyl migration and photodegradation products of furosemide 1-O-acyl glucuronide.
Mizuma T; Benet LZ; Lin ET
J Chromatogr B Biomed Sci Appl; 1998 Oct; 718(1):153-62. PubMed ID: 9832372
[TBL] [Abstract][Full Text] [Related]
8. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers.
Klausner EA; Lavy E; Stepensky D; Cserepes E; Barta M; Friedman M; Hoffman A
J Clin Pharmacol; 2003 Jul; 43(7):711-20. PubMed ID: 12856384
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of furosemide in children: a supplement.
Prandota J
Am J Ther; 2001; 8(4):275-89. PubMed ID: 11441327
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability and diuretic effect of furosemide following administration of tablets and retarded capsules to human subjects.
Yagi N; Kiuchi T; Satoh H; Terashima Y; Kenmotsu H; Sekikawa H; Takada M
Biol Pharm Bull; 1996 Apr; 19(4):616-22. PubMed ID: 8860970
[TBL] [Abstract][Full Text] [Related]
11. Effects of ozolinone, a diuretic active metabolite of etozoline, on renal function. I. Clearance studies in dogs.
Greven J; Heidenreich O
Naunyn Schmiedebergs Arch Pharmacol; 1978 Oct; 304(3):283-7. PubMed ID: 714186
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic interaction between furosemide and metolazone in man.
Marone C; Muggli F; Lahn W; Frey FJ
Eur J Clin Invest; 1985 Oct; 15(5):253-7. PubMed ID: 3935455
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.
Lesne M
Arzneimittelforschung; 1988 Jan; 38(1A):160-3. PubMed ID: 3370062
[TBL] [Abstract][Full Text] [Related]
14. Studies with the optically active isomers of the new diuretic drug ozolinone. II. Inhibition by d-ozolinone of furosemide-induced diuresis.
Greven J; Beckers M; Defrain W; Meywald K; Heidenreich O
Pflugers Arch; 1980 Mar; 384(1):61-4. PubMed ID: 7189867
[TBL] [Abstract][Full Text] [Related]
15. Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling.
Hammarlund MM; Odlind B; Paalzow LK
J Pharmacol Exp Ther; 1985 May; 233(2):447-53. PubMed ID: 3999028
[TBL] [Abstract][Full Text] [Related]
16. Biotransformation of furosemide in kidney transplant patients.
Smith DE; Benet LZ
Eur J Clin Pharmacol; 1983; 24(6):787-90. PubMed ID: 6350024
[TBL] [Abstract][Full Text] [Related]
17. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I).
Ponto LL; Schoenwald RD
Clin Pharmacokinet; 1990 May; 18(5):381-408. PubMed ID: 2185908
[TBL] [Abstract][Full Text] [Related]
18. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide.
Keller E; Hoppe-Seyler G; Mumm R; Schollmeyer P
Eur J Clin Pharmacol; 1981; 20(1):27-33. PubMed ID: 7308269
[TBL] [Abstract][Full Text] [Related]
19. Food: an unrecognized source of loop diuretic resistance.
Bard RL; Bleske BE; Nicklas JM
Pharmacotherapy; 2004 May; 24(5):630-7. PubMed ID: 15162897
[TBL] [Abstract][Full Text] [Related]
20. Perinatal growth restriction decreases diuretic action of furosemide in adult rats.
DuBois BN; Pearson J; Mahmood T; Nguyen D; Thornburg K; Cherala G
Eur J Pharmacol; 2014 Apr; 728():39-47. PubMed ID: 24508521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
